抗ã†ã¤è–¬ã¨QTｃ延長
薬剤ã®æµ·å¤–個人輸入ãªã©ãŒå•é¡Œã«ãªã£ã¦ã‚‹ãŒã€ã‚·ã‚¿ãƒãƒ—ラム（セãƒã‚¯ã‚µï¼‰ã¯ç±³å›½FDAãŒã€è‡´æ»çš„ä¸æ•´è„ˆã¨é–¢é€£ã™ã‚‹ãŸã‚ã€å†ä¸‰è¦å‘Šã—ã¦ã„る薬剤。 ãれ以外ã§ã‚‚ã€æŠ—ã†ã¤è–¬ã¨ã—ã¦ã€ã‚¨ã‚¹ã‚·ã‚¿ãƒãƒ—ラム（レクサプãƒï¼‰ã‚„アミトリプãƒãƒªãƒ³ï¼ˆãƒˆãƒªãƒ—タノール）ã§ã‚‚QTｃ延長ã«æ³¨æ„ãŒå¿…è¦ã€‚ä»–ã€ã‚¿ã‚±ãƒ—ãƒãƒ³ãªã©ã®ãƒ©ãƒ³ã‚½ãƒ—ラゾールã€ã‚ªãƒ¡ãƒ—ラゾールãªã©ã®PPIã€ãƒ–イフェンドãªã©ã®ãƒœãƒªã‚³ãƒŠã‚¾ãƒ¼ãƒ«ãŒæ³¨æ„ã™ã¹ã薬剤ã¨ã—ã¦æŒ™ãŒã‚‹ã€‚ â€æ—¥æœ¬äººã®5人ã«ä¸€äººãŒCYP2C19ã®æ´»æ€§ç•°å¸¸ã‚ã‚Šã€è‡¨åºŠä¸Šæ—¥æœ¬äººã«ã¨ã£ã¦è‡¨åºŠçš„影響ãŒæ‡¸å¿µã•ã‚Œã‚‹CYP分å機構ã§ã‚る†(å‚考　PDF) ã“ã®ãŸã‚ã€ã“れら薬剤ã¯æŠ•ä¸Žã‚’é¿ã‘ã‚‹ã“ã¨ãŒæœ›ã¾ã—ã„ã®ã§ã¯ãƒ»ãƒ»ãƒ» Torsades de pointesãªã©ã®è‡´æ»çš„ä¸æ•´è„ˆã¯å¿ƒå®¤æ€§å†åˆ†æ¥µã®é·å»¶åŒ–ãŒé–¢ä¿‚ã™ã‚‹ã€‚ç„¡æ•°ã®å¸‚販薬ãŒã€"心電図上ã®QT時間延長ã¨é–¢é€£ã™ã‚‹â€å†åˆ†æ¥µæ™‚間延長ã¨é–¢é€£ã™ã‚‹ã€‚市販後調査ã§ç¢ºèªã•ã‚Œå¸‚å ´ã‹ã‚‰æ’¤é€€ã—ãŸè–¬å‰¤ã‚‚å˜åœ¨
ランã‚ング
ランã‚ング
ランã‚ング
リリースã€éšœå®³æƒ…å ±ãªã©ã®ã‚µãƒ¼ãƒ“スã®ãŠçŸ¥ã‚‰ã›
最新ã®äººæ°—エントリーã®é…ä¿¡
j次ã®ãƒ–ックマーク
kå‰ã®ãƒ–ックマーク
lã‚ã¨ã§èªã‚€
eコメント一覧を開ã
oページを開ã
A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder - PMC
Superiority of escitalopram to paroxetine in the treatment of depression - PubMed
Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder - PubMed
http://ijnp.oxfordjournals.org.remote.library.osaka-u.ac.jp/content/11/3/381
Hoschl_Escitalopram.fm
Escitalopram in the treatment of depressed elderly patients - PubMed
Comparison of Toxicity of Acute Overdoses with Citalopram and Escitalopram
Clinical and ECG Effects of Escitalopram Overdose
A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression
More Suicidal Ideation With Nortriptyline vs Escitalopram Among Men, but Both Drugs Decrease Adverse Effects
Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany - PubMed
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder - PubMed
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care - PubMed
The clinical pharmacokinetics of escitalopram - PubMed
Original article 305 Evidence based review of escitalopram in treating major depressive disorder in primary care Thomas R. Einarson The study aimed to summarize clinical data for escitalopram in the treatment of major depressive disorder in primary care.
Escitalopram : a review of its use in the management of major depressive and anxiety disorders - PubMed
Escitalopram in the acute treatment of depressed patients aged 60 years or older - PubMed
Escitalopram prevents relapse in older patients with major depressive disorder - PubMed
New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram - PubMed
{{#tags}}- {{label}}
{{/tags}}